Kornimate/medical-research-clean huggingface dataset:
interest of artificial intelligence in cancer screening colonoscopy

Conditions: Colonoscopy; Colorectal Neoplasms; Intestinal Polyps; Deep Learning

Summary: artificial intelligence (ai) to predict the histology of polyps per colonoscopy, offers a promising solution to reduce variation in colonoscopy performance. this new and innovative non-invasive technology will improve the quality of screening colonoscopies, and reduce the costs of colorectal cancer screening. the aim of the study is to performed a cross-sectional, multi-center study evaluating the diagnostic performance of the cad eye automatic characterization system for the histology of colonic polyps in colorectal cancer screening colonoscopy.

deep learning to predict the histology of polyps per colonoscopy, offers a promising solution to reduce variation in colonoscopy performance. meanwhile, the concept of 'optical biopsy' where in vivo classification of polyps based on enhanced imaging replaces histopathology has not been incorporated into routine practice, largely limited by inter-observer variability and generally meeting accepted standards only in expert settings. real-time decision support software has been developed to detect and characterise polyps, whilst also offering feedback on the technical quality of inspection. this study will evaluate the performance of the cad eye automatic characterization system for the histology compared to histological analysis. and secondary aims : the diagnostic performance of the cad eye automated detection device compared to a standardized video recording with blind independent review. procedure: the screening colonoscopy will be performed by an investigator. the automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without cad eye and image with cad eye). the investigator performing the colonoscopy will be blinded by the results of the cad eye. follow-up: no specific follow-up is planned after colposcopy

Eligibility criteria:
inclusion criteria: * patients over 18 years of age with indication for colonoscopy as part of a screening colonoscopy, after a positive immunological test, and/or for personal or family history of colon cancer (before 60 years), personal history of colonic adenoma. * patient with at least one polyp detected, resect and removed during colonoscopy, for histological analysis exclusion criteria: * guardianship or protection, * pregnancy, * not fluent in french or illiterate, * lack of health care

Keywords: colonoscopy colorectal neoplasms computer aided diagnosis deep learning
the effect of training on nursing qualıty

Conditions: Nurse's Role

Summary: the aim of this study, in a randomized controlled design with pretest, posttest and control groups, is to determine the effect of on-the-job (toolbox) training given to nurses on nursing-sensitive quality indicators (pain management, pressure sores, patient falls, peripheral venous catheter complications and adverse event reporting). it aims to answer are: - does toolbox training have an effect on nursing-sensitive quality indicators? after the training, participants are expected to adapt to quality practices. this study consists of experimental and control groups. experimental and control groups were determined by drawing lots with the help of an external expert. nurses who met the inclusion criteria were included in the lottery. inclusion criteria for the experimental and control groups were determined as follows: * working in one of the hospital's internal medicine or surgical services * having been working in the current service for at least 6 months, apart from past work experience * having completed the orientation process to the hospital and taking responsibility for patient care * voluntarily agree to participate in the study

this study was carried out to determine the effect of toolbox training on nursing-sensitive quality indicators (pain management, pressure sores, patient falls, peripheral venous catheter complications and adverse event reporting) in a randomized controlled, pre-test, post-test, experimental and control group design. the population of the study consisted of nurses working in the inpatient services (except the intensive care units) of a training and research hospital in hatay. a total of 77 nurses working in the experimental and control group services determined by randomization constituted the sample of the research (experimental group: 38 nurses, control group: 39 nurses).

Eligibility criteria:
inclusion criteria: * working in one of the hospital's internal medicine or surgical services * being working in the current service for at least 6 months apart from past work experience * having completed the orientation process to the hospital and taking responsibility for patient care * to voluntarily agree to participate in the study exclusion criteria: * participants who did not meet the inclusion criteria were excluded.

Keywords: quality indicators quality in health quality in nursing
reproducibility and comparison of platelet function assays with aspirin and clopidogrel (mk-0000-167)

Conditions: Healthy Volunteers

Summary: this study will evaluate whether the antiplatelet effects of aspirin 300 mg daily and clopidogrel 75 mg daily can be reproducibly measured using several point of care platelet function assays


Eligibility criteria:
inclusion criteria: * subject has bmi (body mass index) less than 32 kg/m\^ 2 * subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 3 months * subject does not have a history of any bleeding disorder exclusion criteria: * subject is a pregnant or nursing female * subject has a history of multiple and/or severe allergies to drugs or foods, or any history (personal or family) of bleeding disorders (including arterial bleeding, hemorrhage requiring transfusion or urgent intervention) * subject currently uses on a regular basis or has used aspirin or clopidogrel within 21 days prior to screening (including low-dose aspirin and pain relievers, cold, or sinus remedies containing aspirin) * subject currently uses on a regular basis or has used within 2 weeks prior to study start, any other prescription or nonprescription drugs, including nsaids such as ibuprofen, naproxen, cox-ii inhibitors such as celecoxib or etoricoxib, other pain relievers, cold, or sinus remedies containing nsaids, and herbal remedies (e.g., st. john wort) * subject anticipates needing during the study any prescription or nonprescription (including over the counter) preparation, including those that contain aspirin, ibuprofen, or any other nsaid or nsaid-containing product commonly found in pain relievers, cold or sinus remedies * subject has a history of skin conditions (such as dry skin, pruritus, rosacea, eczema) or has a sun burn at the time of screening and is unwilling to avoid excessive sun exposure for the duration of the study * subject regularly uses antacids or other otc medications (4 or more times per month) for symptoms of dyspepsia or has a history of use of prescription ulcer medication such as h2 blockers (e.g., cimetidine, ranitidine, famotidine, nizatidine) or a proton pump inhibitor (omeprazole) within the last 5 years * subject has a history of poor wound healing or a tendency to form keloids
prospective evaluation of myocardial perfusion computed tomography trial

Conditions: Coronary Disease

Summary: the purpose of this study is to evaluate safety and effectiveness of ctp(computed tomography perfusion) guided revascularization vs ffr(fractional flow reserve) guided revascularization


Eligibility criteria:
inclusion criteria: * age 20 and more * diagnosed angina or angina equivalent symptom or positive exercise treadmill test * patients with intermediate- or high-risk probability of cad defined by diamond and forester * 70 % stenosis or more in coronary cta * willing to provide informed, written consent exclusion criteria: * requirement for surgical procedure * cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support * recent stemi (\<5 days) * non stemi, if the cardiac troponin is not stable or starting to decline * left ventricular ejection fraction \<30% * life expectancy \<2 years * impaired renal function with an effective glomerular filtration rate less than 30ml/min/1.73 ㎡ or creatinine more than 2.0 mg/dl * undergoing evaluation for organ transplantation * participation or planned participation in another cardiovascular clinical trial * pregnancy * inability to take dual antiplatelet therapy for six months * previous cabg * left main disease requiring revascularization * any target lesion with in-stent restenosis * nyha class 3 or 4a * severe and persistent angina with severe limitation in everyday living activities (canadian cardiovascular society grading class iv)

Keywords: computed tomography perfusion fractional flow reserve
changes in muscle morphology resulting from anterior cruciate ligament reconstruction

Conditions: Isolated Anterior Cruciate Ligament Rupture

Summary: the aim of this study is to gain new knowledge on the impact of hamstring tendon harvest and apply that knowledge to the treatment and management of patients who undergo anterior cruciate ligament (acl) reconstruction. there are three main components of this study: 1. how do muscle shape, size, strength, and ability to function change following hamstring grafting for acl reconstruction; 2. how does physical activity change following acl reconstruction; 3. is there a difference in outcome if graft harvest is done from the injured versus uninjured limbs


Eligibility criteria:
inclusion criteria: * between 18 and 50 years old; isolated acl rupture confirmed on mri exclusion criteria: * other physical or mental health issues that affect ability to complete rehabilitation and/or study follow-ups

Keywords: anterior cruciate ligament hamstring semitendinosus gracilis graft
safety/efficacy study: opa-6566 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension

Conditions: Primary Open-angle Glaucoma; Ocular Hypertension

Summary: this is a study of the safety, tolerability, pharmacokinetics (measurement of drug levels in the blood), and intraocular pressure lowering effects of opa-6566 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * diagnosis of bilateral primary open-angle glaucoma * diagnosis of ocular hypertension as defined in the protocol exclusion criteria: * any form of glaucoma other than primary open-angle glaucoma in either eye * other ocular conditions as defined by the protocol

Keywords: open-angle glaucoma glaucoma ocular hypertension intraocular pressure
post (prospective observational superfial thrombophlebitis)

Conditions: Thrombophlebitis

Summary: we performed a national cross-sectional and prospective large epidemiological cohort study in patients with st. office- and hospital-based vascular medicine french practitioners enrolled all consecutive patients with a symptomatic st of the lower limbs at least 5 cm long documented by compression ultrasonography. follow-up was three months. all events were adjudicated by a central committee.

between march 2005 and october 2006, 844 patients (median age \[range\]: 65 \[18-98\] years; 547 women) were included. at inclusion, confirmed deep-vein thrombosis and/or symptomatic pulmonary embolism was associated with st in 24.9% (n=210) of patients. among the 600 patients with isolated st (i.e. without deep-vein thrombosis or pulmonary embolism at inclusion), 10.4% (n=56) developed venous thromboembolic complications at three months, including the following symptomatic events: pulmonary embolism (0.4%, n=2), deep-vein thrombosis (2.8%, n=15), extension of st (3.1%, n=17) and recurrence of st (1.9%, n=10). these complications occurred despite the use of various anticoagulant strategies in 90.5% (n=540) of patients; four independent risk factors increased the risk of these complications: male sex, cardiac or respiratory insufficiency, history of deep-vein thrombosis or pulmonary embolism and no history of varicose veins.

Eligibility criteria:
inclusion criteria: * all consecutive patients aged 18 years or over, with a symptomatic st of the lower limbs at least 5 cm long on compression ultrasonography. exclusion criteria: * patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom st had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible

Keywords: superficial thrombophlebitis (st) deep-vein thrombosis symptomatic pulmonary embolism symptomatic superficial thrombophlebitis of the lower limbs
retrospective observational research study to describe the real world use of bosutinib in a single centre in scotland

Conditions: Myeloid Leukemia

Summary: this study will describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia (cml) used in a real world clinical practice setting.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of ph+ cml aged ≥18 years at bosutinib initiation. * patients prescribed bosutinib (irrespective of the phase of their disease) either in normal clinical practice since it received marketing authorisation (27 march 2013) by the ema or via the compassionate use programme prior to marketing authorization. * where required, evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. exclusion criteria: * patients prescribed bosutinib as part of an interventional clinical trial programme. * patients initiated on bosutinib less than 3 months prior to data collection taking place. * patients prescribed bosutinib as exclusively post-allograft therapy.

Keywords: philadelphia chromosome breakpoint cluster region/ abelson (bcr/abl1) retrospective observational chromic myeloid leukemia
feasibility trial of rtms for cannabis use disorder

Conditions: Cannabis

Summary: this small pilot trial will recruit 10 cannabis use disordered participants and apply 20 sessions of rtms in conjunction with a two session brief marijuana dependance counseling treatment paradigm. the investigators are primarily seeking to determine if the proposed paradigm is feasible and well tolerated.

the overarching goal of this proposal is to investigate if a course of excitatory dlpfc rtms is feasible and well tolerated by a group of treatment seeking cud patients (aim1). the investigators are also hoping to preliminarily determine if a course of rtms reduces cannabis cue-induced craving (aim2). additionally the investigators want to preliminarily explore the mechanistic underpinnings of any observed effect by collecting functional magnetic resonance imaging (fmri) data during cannabis cue-administration before and after the treatment course (aim 3). these aims will be addressed through an open label study in which 10 treatment seeking cannabis use disordered participants will be given 20 sessions of active excitatory rtms applied to the dlpfc. tms will be delivered in an accelerated fashion over two weeks (2 sessions each day, five days each week). tms will be applied in conjunction with a validated two-session motivational enhancement therapy (met) behavioral intervention.

Eligibility criteria:
inclusion criteria: 1. participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments. 2. participants must be between the ages of 18 and 60. 3. participants must meet dsm-5 criteria for at least moderate cannabis use disorder, with use of at least 20 / last 28 days. 4. participants must express a desire to quit cannabis. 5. participants must have a positive uds for cannabis during their enrollment visit (confirming they are regular users). exclusion criteria: 1. participants must not be pregnant or breastfeeding. 2. participants must not test positive for any substance other than cannabis on uds during their enrollment visit. 3. participants must not meet moderate or severe use disorder of any other substance with the exception of tobacco use disorder. 4. participants must not be on any medications that have central nervous system effects. 5. participants must not have a history of/or current psychotic disorder or bipolar disorder. 6. participants must not have any other axis i condition requiring current treatment and must have a hrsd24 ≤10 indicating no clinically relevant depressive symptoms. 7. participants must not have a history of dementia or other cognitive impairment. 8. participants must not have active suicidal ideation or a suicide attempt within the past 90 days. 9. participants must not have any contraindications to receiving rtms (e.g. metal implanted above the head, history of seizure, any known brain lesion). 10. participants must not have any unstable general medical conditions.
descriptive analysis: start back screening tool: cross-sectional survey & chart review

Conditions: Back Pain

Summary: keele start back screening tool (ksb) is a practical and validated bio-psychosocial questionnaire that stratifies lower back pain patients into 3 risk groups (low, medium, high), with suggested treatment guidelines for each grouping. the 9-question ksb has been used in chiropractic practice to help guide medical decision making, but its use in chiropractic teaching environments has been limited.

all new lbp patients between the ages of 18-65 years presenting to a chiropractic teaching clinic in dallas, tx between march 05, 2018 and april 06, 2018 were asked to complete the ksb questionnaire. no introduction of the ksb was given to students or faculty. for all patients that completed the ksb, a chart review of the first 4 weeks of care was completed to retrieve patient follow-up information and treatment provided, including: self-reported lbp on a 10-point numerical rating scale (nrs), region of spinal manipulation therapy (smt), and active rehabilitation provided.

Eligibility criteria:
inclusion criteria: * patients between the age of 18-65 years old. exclusion criteria: * none

Keywords: chiropractic screening tool teaching
late feasibility study to evaluate safety and efficacy of awak pd device in subjects with eskd.

Conditions: Chronic Kidney Diseases

Summary: the goal of this late feasibility clinical trial is to evaluate the safety and effectiveness of the automated wearable artificial kidney (awak) peritoneal dialysis (pd) device in subjects with end-stage kidney disease. the main questions it aims to answer are: * the success of awak pd therapies when used in a home-setting * the safety and effectiveness of the awak pd system participants will: * be titrated to find a suitable awak pd prescription * be trained on how to use the awak pd system independently * use the awak pd system at home for at least 7 days


Eligibility criteria:
inclusion criteria: 1. written informed consent to participate in the study. 2. male or female ≥22 years of age. 3. treated with pd for at least 3 months before screening. 4. has weekly kt/vurea (renal + peritoneal) ≥1.7 5. no acute peritonitis, catheter infection, exit site, or subcutaneous tunnel infection within 3 months before screening. exclusion criteria: 1. severe comorbidity or poor general physical/mental health that, in the opinion of the investigator, will not allow the subject to be a good investigation candidate 2. recent (within the previous 6 months) history of major cardiovascular events (e.g., stroke, acute myocardial infarction). 3. diagnosed with new york heart association (nyha) class iii or class iv heart failure. 4. poorly controlled diabetes mellitus as defined by hemoglobin a1c \>9.0% during screening 5. subject has a current abdominal hernia. 6. subject has an active infection requiring systemic antibiotics or antifungal therapy. 7. active infection of hepatitis b and c, or hiv infection at any time.

Keywords: peritoneal dialysis wearable medical device home-based therapy
phase ii pilot study of olsalazine for ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: objectives: i. assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy.

protocol outline: patients are treated with daily olsalazine. the dose is increased each week until the protocol dose is reached. supplemental acetaminophen is allowed; nonsteroidal anti-inflammatory drugs continue unchanged. concurrent sulfasalazine is prohibited.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * meets modified new york diagnostic criteria * active disease, i.e., morning stiffness for more than 30 minutes * failed or experienced nonlife-threatening reaction to prior sulfasalazine * no significant hematologic, hepatic, or renal disease

Keywords: ankylosing spondylitis genetic diseases and dysmorphic syndromes rare disease
a study of ado-trastuzumab emtansine (t-dm1)-induced peripheral neuropathy in her2-positive breast cancer patients

Conditions: Breast Neoplasm

Summary: researchers plan to study the natural history of ado-trastuzumab emtansine (t-dm1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.


Eligibility criteria:
inclusion criteria: * planning to receive three or more doses t-dm1 for her2-positive metastatic breast cancer (any line) or for earlier-stage breast cancer. the patient may have received one dose of t-dm1, prior to study entry if it has not been longer than 14 days since that dose and that the patient will be able to complete the required baseline questionnaire within 14 days of their first dose of t-dm1. * patients with previous use of neurotoxic antineoplastic agents (excluding previous use of t-dm1), pre-existing cipn, or peripheral neuropathy secondary to other causes will be able to be enrolled in the study. * the patient plans to continue clinical follow-up at the same institution, where the patient entered the study. * provide informed consent. * ability to complete questionnaire(s) in english by themselves or with assistance. exclusion criteria: * previous use of t-dm1 * concomitant use of other neurotoxic anticancer agents including cisplatin, carboplatin, oxaliplatin, docetaxel, paclitaxel, vincristine, eribulin, vinorelbine, thalidomide, lenalidomide, bortezomib, or epothilones. if the patient used any of these previously, then they must have been stopped for at least 7 days prior to study entry. * current use of commonly used drugs for the treatment of peripheral neuropathy, including duloxetine, gabapentinoids (pregabalin and gabapentin), venlafaxine, nortriptyline, or amitriptyline (including use of these medications for things other than neuropathy). if the patient used any of these previously, then they must have been stopped for at least 7 days prior to study entry.

Keywords: ado-trastuzumab emtansine (t-dm1) peripheral neuropathy her2-positive